OCULAR THERAPEUTIX, INC (OCUL) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$7.37

From 52W high−56.98%

Volume1.00M

Market cap$1.52B

P/E (TTM)—

P/S (TTM)29.2x

Div yield—

Key dataOct 16, 2026

Open

$7.37

From 52W high

−56.98%

Volume

1.00M

Market cap

$1.52B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.5x

P/E (TTM)

—

RSI (14)

31.5

MomentumView details →

1D Return

−6.10%

YTD Return

−42.59%

SummaryUpdated Jun 1, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company founded in 2006 and headquartered in Bedford, Massachusetts. The company specializes in developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel-based formulation technology. Since going public in 2014, Ocular Therapeutix has evolved from a clinical-stage company into a commercial organization with marketed products and a robust pipeline of sustained-release drug delivery systems for various ocular conditions.

Ask drillr about OCULAR THERAPEUTIX, INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.5x

EV/Sales

19.3x

P/S (TTM)

29.2x

P/B (TTM)

2.9x

ProfitabilityView details →

Gross Margin

87.11%

Net Margin

−579.10%

EBITDA Margin

−546.73%

ROE (TTM)

−57.97%

ROA (TTM)

−44.90%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

−8.14%

EPS YoY

−10.94%

FCF YoY

−42.22%

Revenue CAGR 3Y

+0.21%

EPS CAGR 3Y

−16.39%

EBITDA YoY

−41.94%

MomentumView details →

1D Return

−6.10%

YTD Return

−42.59%

1Y Return

−41.13%

RSI (14)

31.5

vs 50D SMA

−26.86%

vs 200D SMA

−25.43%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

13.11x

Quick Ratio

13.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.35

EPS Surprise

11.49%

Beats (12Q)

4/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

−6.34%

Rev Surprise

2.07%

Financials snapshotView financials →

Revenue (TTM)

52.05M

Net Income (TTM)

−301.45M

Op. CF (TTM)

−238.24M

Next earningsNov 3, 2026 →

Latest newsMore news →

Ocular Therapeutix completed a positive Pre-NDA meeting with the U.S. FDA for its investigational wet AMD candidate AXPAXLI, confirming plans for a 4Q 2026 NDA submission.31d ago

Ocular Therapeutix reported a second-quarter net loss of $0.35 per share, beating the Zacks Consensus Estimate of a $0.40 loss and improving from a $0.39 loss a year earlier.74d ago

Similar companies

uniQure N.V.QURE Structure Therapeutics Inc.GPCR Maze Therapeutics, Inc.MAZE Immunocore Holdings plcIMCR Intellia Therapeutics, Inc.NTLA SinoMab BioScience Limited03681.HK Find similar companies →

Latest newsMore news →

Ocular Therapeutix completed a positive Pre-NDA meeting with the U.S. FDA for its investigational wet AMD candidate AXPAXLI, confirming plans for a 4Q 2026 NDA submission.31d ago Ocular Therapeutix reported a second-quarter net loss of $0.35 per share, beating the Zacks Consensus Estimate of a $0.40 loss and improving from a $0.39 loss a year earlier.74d ago Ocular Therapeutix announced that the FDA is aligned on its plan to submit a new drug application for Axpaxli injection for wet age-related macular degeneration.121d ago